Giovanni Caforio, Bristol Myers Squibb CEO (Nicolas Messyasz/Sipa via AP Images)

Bris­tol My­ers lines up a date with the FDA to ex­pand the foot­print of its $13B heart drug

In April, Bris­tol My­ers Squibb won ap­proval for mava­camten, now mar­ket­ed as Camzyos, to im­prove symp­toms of ob­struc­tive hy­per­trophic car­diomy­opa­thy (oHCM), a con­di­tion in which the heart mus­cle be­comes too thick and blocks blood flow.

Fri­day morn­ing, Bris­tol My­ers an­nounced that its fil­ing for mava­camten in an ad­di­tion­al in­di­ca­tion in a sub­set of pa­tients with oHCM had been ac­cept­ed by the FDA. The new fil­ing cen­ters on the group of pa­tients who have se­vere symp­toms and are re­ferred to sep­tal re­duc­tion ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.